Rima Kaddurah-Daouk

---

09:45 - 10:30 "A Precision Medicine Approach for the Study of NeuroPsychiatric Diseases at the Cross Road Metabolome Genome and Exposome."

---

Dr. Kaddurah-Daouk is a Professor in the Departments of Psychiatry and Behavioral Sciences and Medicine at Duke University. She is a graduate of the American University of Beirut, Department of Biochemistry, with subsequent training at Johns Hopkins (worked with Nobel Laureate Hamilton Smith), Massachusetts General Hospital and the Massachusetts Institute of Technology. She has been a seminal force in the development of applications for metabolomics in the medical field. She co-founded the Metabolomics Society and served more than four years as its founding president, helping create a presence and voice for an interactive metabolomics community (currently over 1000 members).

She helped establish Metabolomics, a leading journal for the field. She co-founded Metabolon, a leading biotechnology company for applications in metabolomics, and two other biotechnology companies. With significant NIH funding (over $80 million over the past 15 years), she established and leads large consortia (more than 120 scientists from over 30 academic institutions). The NIMH-funded Mood Disorder Precision Medicine Consortium (MDPMC) seeks to optimize treatment outcomes in depression (in partnership with the Mayo Clinic, Emory, and several other institutions).

The Alzheimer’s Disease Metabolomics Consortium (ADMC), funded by the National Institute on Aging (NIA) and in partnership with the Alzheimer's Disease Neuroimaging Initiative, is one of six consortia under the Accelerating Medicines Partnership for Treatment of Alzheimer’s Disease (AMPAD) and Molecular Mechanisms of the Vascular Etiology of Alzheimer’s Disease (M²OVE-AD) initiatives set to respond to President Obama’s challenge: “National Plan to Address Alzheimer’s Disease” to treat or prevent Alzheimer’s disease (AD) by 2025. Recently, she established the Alzheimer Gut Microbiome Project, an initiative that includes leadership from the gut microbiome, AD, depression and metabolomics fields with a mission to define a possible role for gut microbiome in AD and other neuropsychiatric diseases and for defining gut brain chemical axis of communication. The project includes Duke, UCSD, Rush, Caltech, and many other academic institutions. Earlier work funded by the National Institute of General Medical Sciences (NIGMS) through the Pharmacometabolomics Research Network established foundations for a new field “Pharmacometabolomics”, which parallels and informs pharmacogenomics and in which metabolic profiles of individuals are used to inform about treatment outcomes. This consortium established foundations for use of metabolomics data as a compliment for genomics data in precision medicine approaches.

Dr. Kaddurah-Daouk leads several initiatives and task groups in Precision Medicine. She has over 170 peer reviewed scientific publications, leads in a large number of active NIH grants  and has more than 60 patents or patent applications. She continue to be ranked as top funded researcher in psychiatry and nationally (Blue Ridge Institute for Medical Research). Kaddurah Daouk is establishing foundations for a global virtual institute for precision health where the metabolome captures net influences of genome, gut microbiome, exposome and diet influences and where big data can inform about health of each individual in real time.